{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T15:13:01Z","timestamp":1791126781713,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2022R1F1A1064142"],"award-info":[{"award-number":["NRF-2022R1F1A1064142"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2018-NR031072"],"award-info":[{"award-number":["RS-2018-NR031072"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024-00342581"],"award-info":[{"award-number":["RS-2024-00342581"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.bcp.2025.116877","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T20:10:18Z","timestamp":1742328618000},"page":"116877","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Targeting RBM39 with Tasisulam enhances TRAIL-induced apoptosis through DR5 upregulation and Bcl-2 downregulation in renal cell carcinoma"],"prefix":"10.1016","volume":"236","author":[{"given":"Ji Hoon","family":"Jang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haein","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heejin","family":"Jun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cho-Young","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo-Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirae","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hunmin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yerim","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebyung","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7143-7769","authenticated-orcid":false,"given":"Eunhee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Jin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2025.116877_b0005","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.628332","article-title":"The TRAIL in the treatment of human cancer: an update on clinical trials","volume":"8","author":"Snajdauf","year":"2021","journal-title":"Front. Mol. Biosci."},{"issue":"6","key":"10.1016\/j.bcp.2025.116877_b0010","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S1074-7613(00)80401-X","article-title":"TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-\u03baB","volume":"7","author":"Schneider","year":"1997","journal-title":"Immunity"},{"key":"10.1016\/j.bcp.2025.116877_b0015","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s10555-018-9728-y","article-title":"Developing TRAIL\/TRAIL death receptor-based cancer therapies","volume":"37","author":"Yuan","year":"2018","journal-title":"Cancer Metastasis Rev."},{"issue":"2","key":"10.1016\/j.bcp.2025.116877_b0020","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41418-022-01059-z","article-title":"Harnessing TRAIL-induced cell death for cancer therapy: a long walk with thrilling discoveries","volume":"30","author":"Montinaro","year":"2023","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.bcp.2025.116877_b0025","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jconrel.2020.07.013","article-title":"TRAIL therapy and prospective developments for cancer treatment","volume":"326","author":"Thapa","year":"2020","journal-title":"J. Control. Release"},{"issue":"5","key":"10.1016\/j.bcp.2025.116877_b0030","doi-asserted-by":"crossref","first-page":"656","DOI":"10.3390\/cancers11050656","article-title":"Countering TRAIL resistance in melanoma","volume":"11","author":"Eberle","year":"2019","journal-title":"Cancers"},{"issue":"15","key":"10.1016\/j.bcp.2025.116877_b0035","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1038\/sj.onc.1205258","article-title":"Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression","volume":"21","author":"Fulda","year":"2002","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.bcp.2025.116877_b0040","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1007\/s10495-017-1375-1","article-title":"Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs)","volume":"22","author":"Rathore","year":"2017","journal-title":"Apoptosis"},{"issue":"12","key":"10.1016\/j.bcp.2025.116877_b0045","first-page":"1051","volume":"1","author":"Ng","year":"2002","journal-title":"Mol. Cancer Ther."},{"issue":"4","key":"10.1016\/j.bcp.2025.116877_b0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010226","article-title":"Activation of the Akt survival pathway contributes to TRAIL resistance in cancer cells","volume":"5","author":"Xu","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2025.116877_b0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12860-018-0179-7","article-title":"Shikonin sensitizes A549 cells to TRAIL-induced apoptosis through the JNK, STAT3 and AKT pathways","volume":"19","author":"Guo","year":"2018","journal-title":"BMC Cell Biol."},{"issue":"1","key":"10.1016\/j.bcp.2025.116877_b0060","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1535-7163.MCT-11-0434","article-title":"TRAIL signaling and synergy mechanisms used in TRAIL-based combination therapies","volume":"11","author":"Hellwig","year":"2012","journal-title":"Mol. Cancer Ther."},{"issue":"5","key":"10.1016\/j.bcp.2025.116877_b0065","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.3892\/ol.2014.1922","article-title":"TRAIL combinations: the new \u2018trail\u2019for cancer therapy","volume":"7","author":"Refaat","year":"2014","journal-title":"Oncol. Lett."},{"issue":"23","key":"10.1016\/j.bcp.2025.116877_b0070","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.3390\/cells11233717","article-title":"Targeting TRAIL death receptors in triple-negative breast cancers: challenges and strategies for cancer therapy","volume":"11","author":"Kundu","year":"2022","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.bcp.2025.116877_b0075","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1158\/1078-0432.CCR-08-0144","article-title":"Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy","volume":"15","author":"Kang","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"16","key":"10.1016\/j.bcp.2025.116877_b0080","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.3390\/cancers14164059","article-title":"Epidemiology and prevention of renal cell carcinoma","volume":"14","author":"Makino","year":"2022","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.bcp.2025.116877_b0085","first-page":"77","article-title":"Therapeutic challenges in renal cell carcinoma","volume":"3","author":"Penticuff","year":"2015","journal-title":"Am. J. Clin. Exp. Urol."},{"key":"10.1016\/j.bcp.2025.116877_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116805","article-title":"Targeting apoptosis in clear cell renal cell carcinoma","volume":"175","author":"Kowalewski","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"9","key":"10.1016\/j.bcp.2025.116877_b0095","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1158\/1535-7163.MCT-05-0522","article-title":"Gene therapy with TRAIL against renal cell carcinoma","volume":"5","author":"Matsubara","year":"2006","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.bcp.2025.116877_b0100","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/s41420-021-00598-7","article-title":"RNA-binding protein 39: a promising therapeutic target for cancer","volume":"7","author":"Xu","year":"2021","journal-title":"Cell Death Discov."},{"issue":"12","key":"10.1016\/j.bcp.2025.116877_b0105","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1111\/bph.15331","article-title":"RNA\u2010binding motif protein 39 (RBM39): an emerging cancer target","volume":"179","author":"Xu","year":"2022","journal-title":"Br. J. Pharmacol."},{"issue":"18","key":"10.1016\/j.bcp.2025.116877_b0110","doi-asserted-by":"crossref","first-page":"4859","DOI":"10.1111\/jcmm.17517","article-title":"Systematic pan-cancer analysis identifies RBM39 as an immunological and prognostic biomarker","volume":"26","author":"Zhang","year":"2022","journal-title":"J. Cell Mol. Med."},{"issue":"2","key":"10.1016\/j.bcp.2025.116877_b0115","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1074\/jbc.M110417200","article-title":"Molecular cloning and characterization of CAPER, a novel coactivator of activating protein-1 and estrogen receptors","volume":"277","author":"Jung","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"6336","key":"10.1016\/j.bcp.2025.116877_b0120","doi-asserted-by":"crossref","DOI":"10.1126\/science.aal3755","article-title":"Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15","volume":"356","author":"Han","year":"2017","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.bcp.2025.116877_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2019.09.079","article-title":"Aryl sulfonamides degrade RBM39 and RBM23 by recruitment to CRL4-DCAF15","volume":"29","author":"Ting","year":"2019","journal-title":"Cell Rep."},{"issue":"5","key":"10.1016\/j.bcp.2025.116877_b0130","first-page":"1237","article-title":"Novel acyl sulfonamide LY573636-sodium: effect on hematopoietic malignant cells","volume":"20","author":"Haritunians","year":"2008","journal-title":"Oncol. Rep."},{"issue":"11","key":"10.1016\/j.bcp.2025.116877_b0135","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1158\/1535-7163.MCT-11-0323","article-title":"Tasisulam sodium, an antitumor agent that inhibits mitotic progression and induces vascular normalization","volume":"10","author":"Meier","year":"2011","journal-title":"Mol. Cancer Ther."},{"issue":"22","key":"10.1016\/j.bcp.2025.116877_b0140","doi-asserted-by":"crossref","first-page":"5367","DOI":"10.1021\/jm030594r","article-title":"Acyl sulfonamide anti-proliferatives: benzene substituent structure\u2212 activity relationships for a novel class of antitumor agents","volume":"47","author":"Lobb","year":"2004","journal-title":"J. Med. Chem."},{"issue":"9_Supplement","key":"10.1016\/j.bcp.2025.116877_b0145","first-page":"3318","article-title":"LY573636 Na+ promotes cell death by inducing reactive oxygen species (ROS) in tumor cells","volume":"68","author":"Gutowski","year":"2008","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.bcp.2025.116877_b0150","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1517\/14728222.11.10.1299","article-title":"TRAIL in cancer therapy: present and future challenges","volume":"11","author":"Merino","year":"2007","journal-title":"Expert Opin. Ther. Targets"},{"issue":"11","key":"10.1016\/j.bcp.2025.116877_b0155","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1124\/dmd.104.000323","article-title":"Tissue distribution, stability, and pharmacokinetics of Apo2 ligand\/tumor necrosis factor-related apoptosis-inducing ligand in human colon carcinoma COLO205 tumor-bearing nude mice","volume":"32","author":"Xiang","year":"2004","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2025.116877_b0160","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jconrel.2022.07.004","article-title":"TRAIL & EGFR affibody dual-display on a protein nanoparticle synergistically suppresses tumor growth","volume":"349","author":"Jun","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bcp.2025.116877_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2024.102474","article-title":"CD13-targeting and TRAIL-displaying protein nanoparticles effectively induce apoptotic cell death of acute myeloid leukemia, prolonging survival in mouse models","volume":"59","author":"Jun","year":"2024","journal-title":"Nano Today"},{"issue":"10","key":"10.1016\/j.bcp.2025.116877_b0170","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.bbamcr.2012.07.003","article-title":"The molecular mechanism of apoptosis upon caspase-8 activation: quantitative experimental validation of a mathematical model","volume":"1823","author":"Kominami","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bcp.2025.116877_b0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2121-14-32","article-title":"Caspase-9, caspase-3 and caspase-7 have distinct roles during intrinsic apoptosis","volume":"14","author":"Brentnall","year":"2013","journal-title":"BMC Cell Biol."},{"key":"10.1016\/j.bcp.2025.116877_b0180","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/BF02761527","article-title":"Correlation between the sensitivity to TRAIL and the expression level of DR5 on the surface of tumor cells","volume":"2","author":"Ma","year":"2005","journal-title":"Chin. J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2025.116877_b0185","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s12272-018-01103-y","article-title":"Elucidation for modulation of death receptor (DR) 5 to strengthen apoptotic signals in cancer cells","volume":"42","author":"Min","year":"2019","journal-title":"Arch. Pharm. Res."},{"issue":"1","key":"10.1016\/j.bcp.2025.116877_b0190","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/cdd.2017.186","article-title":"BCL-2 family proteins: changing partners in the dance towards death","volume":"25","author":"Kale","year":"2018","journal-title":"Cell Death Differ."},{"issue":"1","key":"10.1016\/j.bcp.2025.116877_b0195","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrm2308","article-title":"The BCL-2 protein family: opposing activities that mediate cell death","volume":"9","author":"Youle","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"11","key":"10.1016\/j.bcp.2025.116877_b0200","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/s41401-019-0287-8","article-title":"TRAIL-based gene delivery and therapeutic strategies","volume":"40","author":"Zhong","year":"2019","journal-title":"Acta Pharmacol. Sin."},{"issue":"37","key":"10.1016\/j.bcp.2025.116877_b0205","doi-asserted-by":"crossref","first-page":"6261","DOI":"10.1038\/sj.onc.1207830","article-title":"Histone deacetylase inhibitors upregulate death receptor 5\/TRAIL-R2 and sensitize apoptosis induced by TRAIL\/APO2-L in human malignant tumor cells","volume":"23","author":"Nakata","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2025.116877_b0210","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11050645","article-title":"Histone deacetylase inhibitors sensitize TRAIL-induced apoptosis in colon cancer cells","volume":"11","author":"Zhang","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.bcp.2025.116877_b0215","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/hep.21555","article-title":"TRAIL\/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window","volume":"45","author":"Koschny","year":"2007","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.bcp.2025.116877_b0220","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s11060-009-0010-6","article-title":"Bortezomib sensitizes primary human esthesioneuroblastoma cells to TRAIL-induced apoptosis","volume":"97","author":"Koschny","year":"2010","journal-title":"J Neurooncol"},{"issue":"11","key":"10.1016\/j.bcp.2025.116877_b0225","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/s41419-018-1160-2","article-title":"Sensitization of glioblastoma cells to TRAIL-induced apoptosis by IAP- and Bcl-2 antagonism","volume":"9","author":"Lincoln","year":"2018","journal-title":"Cell Death Dis."},{"issue":"2","key":"10.1016\/j.bcp.2025.116877_b0230","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10549-012-2352-6","article-title":"Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-alpha-independent mechanism","volume":"137","author":"Allensworth","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"issue":"3","key":"10.1016\/j.bcp.2025.116877_b0235","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00280-011-1763-0","article-title":"ABT-263 sensitizes TRAIL-resistant hepatocarcinoma cells by downregulating the Bcl-2 family of anti-apoptotic protein","volume":"69","author":"Wang","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"3","key":"10.1016\/j.bcp.2025.116877_b0240","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/cdd.2013.179","article-title":"Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1","volume":"21","author":"Lemke","year":"2014","journal-title":"Cell Death Differ."},{"issue":"47","key":"10.1016\/j.bcp.2025.116877_b0245","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abj5405","article-title":"Targeting the spliceosome through RBM39 degradation results in exceptional responses in high-risk neuroblastoma models","volume":"7","author":"Singh","year":"2021","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.bcp.2025.116877_b0250","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11010068","article-title":"Indisulam reduces viability and regulates apoptotic gene expression in pediatric high-grade glioma cells","volume":"11","author":"Moncao","year":"2022","journal-title":"Biomedicines"},{"issue":"4","key":"10.1016\/j.bcp.2025.116877_b0255","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41419-021-03567-1","article-title":"Splicing reprogramming of TRAIL\/DISC-components sensitizes lung cancer cells to TRAIL-mediated apoptosis","volume":"12","author":"Voss","year":"2021","journal-title":"Cell Death Dis."},{"issue":"11","key":"10.1016\/j.bcp.2025.116877_b0260","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/onc.2013.86","article-title":"Downregulation of serine\/arginine-rich splicing factor 3 induces G1 cell cycle arrest and apoptosis in colon cancer cells","volume":"33","author":"Kurokawa","year":"2014","journal-title":"Oncogene"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000629522500139X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000629522500139X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T15:24:17Z","timestamp":1762097057000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000629522500139X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":52,"alternative-id":["S000629522500139X"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2025.116877","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting RBM39 with Tasisulam enhances TRAIL-induced apoptosis through DR5 upregulation and Bcl-2 downregulation in renal cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2025.116877","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116877"}}